Kezar Life Sciences Reports on Shareholder Vote Matters

TL;DR

Kezar Life Sciences held a shareholder vote on June 18th. Details filed 8-K.

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on June 21, 2024, reporting on matters submitted to a vote of security holders on June 18, 2024. The filing details the company's principal executive offices located at 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.

Why It Matters

This filing indicates that Kezar Life Sciences held a vote of its security holders, which is a standard corporate governance event that can signal important decisions or approvals.

Risk Assessment

Risk Level: low — This is a routine corporate filing related to a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Kezar Life Sciences, Inc. (company) — Registrant
• June 18, 2024 (date) — Date of earliest event reported
• June 21, 2024 (date) — Date of report
• 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Mark

Filing Documents

• kzr-20240618.htm (8-K) — 53KB
• 0000950170-24-076234.txt ( ) — 161KB
• kzr-20240618.xsd (EX-101.SCH) — 23KB
• kzr-20240618_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2024, the Company held its annual meeting of stockholders. The final results for each of the proposals submitted to a vote of the Company's stockholders at the meeting are set forth below. The proposals set forth below are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024. Proposal 1 : The Company's stockholders elected the two nominees of the Company's board of directors to serve as Class III directors until the 2027 annual meeting of stockholders, or until their successors are duly elected and qualified, by the votes set forth in the table below: Nominee Votes For Votes Withheld Broker Non-Votes Christopher Kirk, Ph.D. 34,221,909 12,897,306 14,120,365 John Fowler 33,809,463 13,309,752 14,120,365 Proposal 2 : The Company's stockholders did not approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the Company's definitive proxy statement by the votes set forth in the table below: Votes For Votes Against Abstain Broker Non-Votes 19,831,332 27,203,746 84,137 14,120,365 Proposal 3 : The Company's stockholders recommended, on an advisory basis, a frequency of "one year" for the advisory vote to approve the compensation paid to the Company's named executive officers by the votes set forth in the table below: 1 Year 2 Years 3 Years Abstain 46,911,276 79,026 78,009 50,904 After taking into consideration the foregoing voting results and the prior recommendation of the Company's Board of Directors (the "Board") in favor of an annual advisory stockholder vote on the compensation of the Company's named executive officers ("Say-on-Pay"), the Company will hold future Say-on-Pay votes on an annual basis. The Company will continue to hold Say-on-Pay votes on an annual basis until the occurrence of the next

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: June 21, 2024 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR